Inventiva (NASDAQ:IVA) Shares Gap Up – What’s Next?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped up prior to trading on Wednesday . The stock had previously closed at $4.77, but opened at $4.92. Inventiva shares last traded at $4.84, with a volume of 159,531 shares trading hands.

Analyst Upgrades and Downgrades

IVA has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $15.38.

Inventiva Stock Up 1.1%

The stock has a 50 day moving average of $4.43 and a two-hundred day moving average of $5.05.

Institutional Investors Weigh In On Inventiva

Institutional investors have recently made changes to their positions in the stock. Creative Planning acquired a new position in shares of Inventiva during the 2nd quarter worth $32,000. Millennium Management LLC acquired a new stake in shares of Inventiva in the third quarter valued at about $649,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the third quarter valued at about $116,000. UBS Group AG boosted its holdings in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after buying an additional 2,634,580 shares in the last quarter. Finally, Simplify Asset Management Inc. purchased a new stake in Inventiva during the fourth quarter worth about $1,570,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.